Intravenous sulprostone and uterine scarring based upon 22 cases of therapeutic abortion during 2nd and 3rd trimesters of pregnancy.
A preliminary study in 22 patients with uterine scarring was undertaken using sulprostone by intravenous infusion when therapeutic abortion was deemed necessary during the 2nd and 3rd trimesters of pregnancy. The dosage used was 500 micrograms by slow infusion lasting 10 h. There were no cases of ruptured uterus. Adverse reactions were absent. Results were satisfactory. Mean induction-expulsion duration: 11 h. Expulsion rate in 24 h: 63%. With strict monitoring and in a specialized center, this technique may be suggested when a late therapeutic abortion with a scarred uterus is indicated.
Marpeau
L
L
Department of Gynecology and Obstetrics, Saint Antoine Hospital, Paris, France.
Percque
M
M
Larue
L
L
Guettier
X
X
Jault
T
T
Pigne
A
A
Barrat
J
J
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000032:Abortion, Therapeutic; D000328:Adult; D002921:Cicatrix / Q000150:complications*; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D016896:Treatment Outcome; D014591:Uterine Diseases / Q000150:complications*
D000020:Abortifacient Agents, Nonsteroidal; C016767:sulprostone; D015232:Dinoprostone